CDK4 and breast carcinoma: This result was supported by a systematic review and meta-analysis of retrospective real-world data on the use of CDK4/6 inhibitors in older and younger patients with breast cancer, indicating that Palbociclib and Ribociclib provided a better survival benefit to elderly patients [32].